Clinical Trial Update: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) [Phase 1, Phase 2]

View source ↗

Summary

The Cleveland Clinic-sponsored study evaluating mesenchymal stem cells for medically refractory ulcerative colitis in phase 1/2 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Ulcerative Colitis | Phase 1, Phase 2 | Status: TERMINATED